CN110787317A - Department of anesthesia uses hemostatic sponge - Google Patents
Department of anesthesia uses hemostatic sponge Download PDFInfo
- Publication number
- CN110787317A CN110787317A CN201911023115.1A CN201911023115A CN110787317A CN 110787317 A CN110787317 A CN 110787317A CN 201911023115 A CN201911023115 A CN 201911023115A CN 110787317 A CN110787317 A CN 110787317A
- Authority
- CN
- China
- Prior art keywords
- fiber
- modified
- hemostatic
- chitosan
- hemostatic sponge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/36—Surgical swabs, e.g. for absorbency or packing body cavities during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/88—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds
- D01F6/92—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds of polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B2017/12004—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord for haemostasis, for prevention of bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Textile Engineering (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Reproductive Health (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
The invention discloses a hemostatic sponge for anesthesia department, which relates to the technical field of medicine and health, and comprises a non-woven fabric surface layer and a fiber framework layer, wherein the fiber framework layer comprises a plurality of overlapped fiber nets, the fiber nets are formed by weaving modified polycaprolactone nano fibers and have a porous network structure, hemostatic gel is filled in gaps of the fiber framework layer, the hemostatic gel is obtained by compounding and crosslinking butyrylamide-modified hyaluronic acid, doubly-linked dopamine and modified chitosan and has a mutually-communicated porous network structure, the modified chitosan is prepared by modifying chitosan through quaternary ammonium salt, and the quaternary ammonium salt is any one of 3-chloro-2-hydroxypropyl trimethyl ammonium chloride and glycidyl trimethyl ammonium chloride. The hemostatic sponge for the anesthesia department can rapidly stop bleeding, can effectively prevent external bacteria from invading a wound in the using process, and reduces inflammatory reaction of the wound surface.
Description
Technical Field
The invention relates to the technical field of medicine and health, in particular to a hemostatic sponge for an anesthesia department.
Background
Today, medical technology is more and more developed, many diseases can be treated by means of operation, and during the operation, anesthesia is inevitably needed to the patient, so that pain or discomfort of the patient during operation or invasive operation is relieved. In general, during the anesthesia operation, the operation procedures such as arterial or intravenous injection, puncture catheter placement, and catheter extraction, which are in direct contact with the blood vessel, are involved. Therefore, the wound caused in the operation process usually needs to be treated with the medical sponge which can rapidly stop bleeding and sterilize and inhibit bacteria in the field.
Traditional hemostatic sponge, mostly realize stanching and other auxiliary function through the additive of medicine or other auxiliary function at surface coating hemostatic function, when using, need cover hemostatic sponge on bleeding point, then fix hemostatic sponge on skin through adhesive cement or adhesive tape, it is slow at the in-process hemostasis speed of use, and outside bacterium can invade the wound, can aggravate the inflammatory reaction of the surface of a wound, influence hemostatic effect and security of use.
Disclosure of Invention
In view of the above problems, an object of the present invention is to provide a hemostatic sponge for anesthesia department, which can rapidly stop bleeding, effectively prevent external bacteria from invading into a wound during the use process, and reduce inflammatory reaction of the wound.
The invention solves the technical problems by the following technical means:
the hemostatic sponge comprises a non-woven fabric surface layer and a fiber framework layer, wherein the fiber framework layer comprises a plurality of fiber nets which are overlapped together, the fiber nets are formed by weaving modified polycaprolactone nano fibers and have a porous network-shaped structure, hemostatic gel is filled in gaps of the fiber framework layer, and is obtained by compounding and crosslinking butyramide-modified hyaluronic acid, double-bonded dopamine and modified chitosan, and has a mutually-communicated porous network-shaped structure.
According to the hemostatic sponge for the anesthesia department, the hemostatic gel is supported by the fiber framework layer, so that the hemostatic sponge can be better covered on a wound surface, excessive deformation caused by external force cannot be generated, the hemostatic gel of the wound surface becomes thin and even breaks and lacks, the wound surface and the external environment can be effectively isolated to a certain extent, external bacteria are prevented from invading the wound, inflammatory reaction of the wound surface is aggravated, and compared with the existing hemostatic sponge, the hemostatic sponge for the anesthesia department is higher in loading capacity of the fiber framework layer, so that a wound with higher bleeding amount can be treated, and the application range of the hemostatic sponge is widened to a certain extent.
Further, the mass ratio of the butyramide-modified hyaluronic acid to the doubly-bonded dopamine to the modified chitosan is 3:1: 5.
Further, the modified chitosan is prepared by modifying chitosan with quaternary ammonium salt, wherein the quaternary ammonium salt is any one of 3-chlorine-2-hydroxypropyl trimethyl ammonium chloride and epoxypropyl trimethyl ammonium chloride.
The amino on the quaternary ammonium salt modified chitosan and the photoproduction aldehyde group on the butyramide modified hyaluronic acid are reacted and crosslinked, so that the mechanical property of the hemostatic gel is improved, and meanwhile, the photoproduction aldehyde group modified by the butyramide can also react with the amino on the tissue at the contact interface of the hemostatic gel and the human tissue, so that the adhesive force between the hemostatic gel and the human tissue is improved; in addition, after the chitosan is modified by the quaternary ammonium salt, the adsorption performance of the chitosan on negative particles is improved, and blood is negatively charged, so that the modified chitosan can promote blood coagulation, and the catechol functional group on the doubly-bonded dopamine can improve the cell affinity of the hemostatic gel, so that the hemostatic gel has good biocompatibility and cell adhesion, can promote wound healing and protect wounds from bacterial infection.
Furthermore, the modified polycaprolactone nanofiber is prepared by taking polycaprolactone and modified silk fibroin as main raw materials and performing electrostatic spinning, and the modified silk fibroin is prepared by modifying and modifying the silk fibroin through polylactic acid.
The polycaprolactone has good biocompatibility and degradability, and can induce platelets to adhere to the surface of the modified polycaprolactone nanofiber by adding the silk fibroin, so that the viscosity of blood is increased, the hemostasis performance is improved, the silk fibroin can activate blood coagulation factors in the blood and induce thrombin to be generated, and then the porous structure of the hemostasis gel is combined, so that liquid substances in the blood can be absorbed, the coagulation generation is promoted, the hemostasis time can be shortened, the requirement of rapid hemostasis is met, meanwhile, the addition of the silk fibroin can regulate and control the inflammatory reaction of a wound surface to a certain extent, the modified chitosan in the hemostasis gel is combined, the two interact, the invasion of external bacteria can be prevented, the inflammatory reaction of the wound surface can be reduced, and the healing of the wound surface can be better promoted.
Furthermore, the non-woven fabric surface layer is mainly made of fibers through point bonding and hot rolling, and the fibers are one or a mixture of more than two of polylactic acid fibers, polyurethane fibers, polyvinyl alcohol fibers and acetate fibers.
The non-woven fabric surface layer prepared by point bonding and hot pressing is relatively fluffy, and the bonding performance between the hemostatic gel and the non-woven fabric surface layer can be improved to a certain degree.
In addition, the invention also discloses a preparation method of the hemostatic sponge for the anesthesia department, which comprises the following steps:
preparing a non-woven fabric surface layer: opening and carding fibers, then paving the fibers into a fiber web, and then carrying out point bonding and hot rolling on the fiber web to obtain a non-woven fabric surface layer;
preparation of the fiber skeleton layer: overlapping multiple layers of fiber nets together, soaking the fiber nets in a soft fluffing agent, performing ultrasonic treatment for 4-6 hours under intermittent pulse type ultrasonic waves, taking out the fiber nets, and naturally drying the fiber nets to obtain a fiber framework layer;
filling: taking modified chitosan, stirring and dissolving the modified chitosan into 0.5 wt% of acetic acid solution, adding glycerol and a cross-linking agent, stirring for 20min by using a foaming device to obtain a modified chitosan solution, adding butyramide-modified hyaluronic acid into deionized water, stirring and dissolving, adding doubly-bonded dopamine, dropwise adding the modified chitosan solution, obtaining a hemostatic gel precursor solution after dropwise adding is completed, placing a fiber skeleton layer into a mold, pouring the hemostatic gel precursor solution into the mold, standing for 12h under the ultraviolet light condition, and freeze-drying to obtain the fiber skeleton layer filled with the hemostatic gel;
preparing a hemostatic sponge: heating the prepared fiber skeleton layer filled with hemostatic gel to 30-35 deg.C, covering with non-woven fabric surface layer, heating to 50-60 deg.C, keeping the temperature for 5min, taking out, and cooling to obtain hemostatic sponge.
The multi-layer fiber net is treated by the fluffy softener, the softness of the fiber net is increased, and the distance between two adjacent layers of fiber nets can be increased to a certain degree, so that the fluffy degree of the fiber framework layer is increased, and more hemostatic gel can be loaded.
Furthermore, the frequency of the intermittent pulse type ultrasonic is 25KHz, the power is 100W, the pulse working time is 3s, and the pulse interval time is 5 s.
Further, the preparation method of the fiber web comprises the following steps: aggregating the modified poly caprolactone nano fibers to form modified poly caprolactone nano fiber bundles with the diameter of 0.1-0.2mm, soaking the modified poly caprolactone nano fiber bundles in deionized water, freezing and storing for 10-12h at-10-0 ℃, then taking out, naturally melting at normal temperature, airing the modified poly caprolactone nano fiber bundles in a ventilated and cool place, placing the dried modified poly caprolactone nano fiber bundles in a microwave oven for microwave treatment for 15-20min, taking out, drying and weaving to obtain the fiber mesh.
After the modified polycaprolactone nanofiber bundle is subjected to freezing treatment, the distance between the modified polycaprolactone nanofibers is increased to a certain extent, the looseness of the modified polycaprolactone nanofiber bundle is improved, and the modified polycaprolactone nanofiber can absorb energy in microwaves after microwave treatment, so that the modified polycaprolactone nanofiber bundle is further fluffy, and the specific surface area of the modified polycaprolactone nanofiber bundle is increased.
Further, the preparation method of the modified polycaprolactone nanofiber comprises the following steps: respectively stirring and dissolving the polycaprolactone and the polylactic acid modified silk fibroin in hexafluoroisopropanol according to a mass ratio of 7:3 to obtain a spinning solution with the mass fraction of 8%, transferring the spinning solution into an injector, and performing electrostatic spinning under the conditions that the spinning voltage is 12kV and the receiving distance is 13cm to obtain the modified polycaprolactone nanofiber.
The invention has the beneficial effects that:
according to the hemostatic sponge for the anesthesia department, the hemostatic gel is supported by the fiber framework layer, so that the hemostatic sponge can be better covered on a wound surface, excessive deformation caused by external force cannot be generated, and the hemostatic gel of the wound surface becomes thin and even breaks and lacks, therefore, the wound surface and the external environment can be effectively isolated to a certain extent, external bacteria are prevented from invading the wound, inflammatory reaction of the wound surface is aggravated, and the specific surface area of the fiber framework layer is increased due to the structural arrangement of the fiber framework layer, the loading capacity of the fiber framework layer on the hemostatic gel is increased, and the hemostatic capacity of the hemostatic sponge is improved.
Detailed Description
The present invention will be described in detail with reference to specific examples below:
the invention relates to a hemostatic sponge for anesthesia department, which comprises a non-woven fabric surface layer and a fiber framework layer, wherein the fiber framework layer comprises a plurality of fiber nets overlapped together, each fiber net is formed by weaving modified polycaprolactone nano fibers and has a porous network structure, the modified polycaprolactone nano fibers are prepared by taking polycaprolactone and polylactic acid modified silk fibroin as raw materials and carrying out electrostatic spinning, and hemostatic gel is filled in gaps of the fiber framework layer, wherein the hemostatic gel is prepared by carrying out composite crosslinking on butyramide modified hyaluronic acid, doubly-bonded dopamine and modified chitosan and has a mutually communicated porous network structure, the modified chitosan is prepared by modifying chitosan through quaternary ammonium salt, and the quaternary ammonium salt is any one of 3-chloro-2-hydroxypropyl trimethyl ammonium chloride and epoxy propyl trimethyl ammonium chloride.
Example one
Preparing modified polycaprolactone nanofibers: respectively stirring and dissolving polycaprolactone and polylactic acid modified silk fibroin in hexafluoroisopropanol according to a mass ratio of 7:3 to obtain spinning solution with the total mass fraction of 8% of polycaprolactone and polylactic acid modified silk fibroin, transferring the spinning solution into an injector, and performing electrostatic spinning under the conditions that the propelling speed is 0.5ml/h, the spinning electrostatic pressure is 20KV and the acceptance distance is 15cm to obtain the modified polycaprolactone nanofiber.
Preparation of the fiber web: aggregating the modified polycaprolactone nanofibers to form modified polycaprolactone nanofiber bundles with the diameter of 0.2mm, completely soaking the modified polycaprolactone nanofiber bundles in deionized water, freezing and storing for 10 hours at the temperature of-5 ℃, then taking out, naturally melting at normal temperature, airing the modified polycaprolactone nanofiber bundles in a ventilated and cool place, placing the dried modified polycaprolactone nanofiber bundles in a microwave oven, performing microwave treatment for 18 minutes at the power of 650W, taking out, drying and weaving to obtain the fiber mesh.
Preparing modified chitosan: adding 1g of chitosan into every 100ml of 1% acetic acid solution, stirring and dissolving, dropwise adding 1mol/L NaOH solution until the chitosan is swelled and separated out, then adding the chitosan into 50 Vol% isopropanol aqueous solution, stirring and dispersing, heating to 80 ℃, adding 3-chloro-2-hydroxypropyl trimethyl ammonium chloride for 3 times, adding 3-chloro-2-hydroxypropyl trimethyl ammonium chloride with the same mass of chitosan every time, stirring and reacting for 8 hours, precipitating the reaction solution by using an acetone-ethanol mixed solution, centrifuging, washing and drying to obtain the modified chitosan, wherein the acetone-ethanol mixed solution is obtained by stirring and mixing acetone and ethanol according to the volume ratio of 7: 3.
Preparation of butyramide-modified hyaluronic acid: stirring and dissolving hyaluronic acid in distilled water, adding hydroxybenzotriazole, butyramide and 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride, wherein the mass ratio of the hyaluronic acid to the distilled water to the hydroxybenzotriazole to the butyramide to the 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride is 4:15:2:1:1, stirring and mixing uniformly, reacting at room temperature for 48 hours, dialyzing for 1d by using a dilute hydrochloric acid solution with the pH of 3.5 after the reaction is finished, dialyzing for 1d by using deionized water, and freeze-drying to obtain the butyramide modified hyaluronic acid.
Preparing a non-woven fabric surface layer: the fiber is loosened, carded and then laid into a fiber web, and the fiber web is hot rolled by point bonding by adopting a conventional technology to obtain a non-woven fabric surface layer.
Preparation of the fiber skeleton layer: the fiber skeleton layer is prepared by overlapping a plurality of fiber webs together, soaking the fiber webs in a fluffy softening agent, performing ultrasonic treatment for 5 hours under an intermittent pulse type ultrasonic wave with the frequency of 25KHz and the power of 100W, taking out the fiber skeleton layer, and performing natural air drying on the fiber skeleton layer, wherein the pulse working time of the intermittent pulse type ultrasonic wave is 3s, and the pulse interval time is 5 s.
Filling: adding 1g of modified chitosan into every 50ml of 0.5 wt% acetic acid solution, stirring and dissolving, then adding glycerol and glutaraldehyde, wherein the mass ratio of the glycerol to the glutaraldehyde is 3:2:0.1 in the embodiment, stirring for 20min by using a foaming device to obtain a modified chitosan solution, adding butyramide-modified hyaluronic acid into deionized water, stirring and dissolving, then adding double-bonded dopamine, dropwise adding the modified chitosan solution, and obtaining a hemostatic gel precursor solution after dropwise adding, wherein the mass ratio of the butyramide-modified hyaluronic acid, the double-bonded dopamine, the modified chitosan and the deionized water is 3:1:5:10, placing the fiber skeleton layer into a mold, pouring the hemostatic gel precursor solution into the mold, standing for 12h under the ultraviolet light condition, and freeze-drying to obtain the fiber skeleton layer filled with the hemostatic gel.
Preparing a hemostatic sponge: and heating the prepared fiber framework layer filled with the hemostatic gel to 32 ℃, covering a non-woven fabric surface layer, heating to 60 ℃, preserving heat for 5min, taking out and cooling to obtain the hemostatic sponge.
Example two
Preparing modified polycaprolactone nanofibers: respectively stirring and dissolving polycaprolactone and polylactic acid modified silk fibroin in hexafluoroisopropanol according to a mass ratio of 6:4 to obtain spinning solution with the total mass fraction of 8% of polycaprolactone and polylactic acid modified silk fibroin, transferring the spinning solution into an injector, and performing electrostatic spinning under the conditions that the propelling speed is 0.8ml/h, the spinning electrostatic pressure is 25KV and the acceptance distance is 18cm to obtain the modified polycaprolactone nanofiber.
Preparation of the fiber web: gathering the modified polycaprolactone nanofibers to form modified polycaprolactone nanofiber bundles with the diameter of 0.15mm, completely soaking the modified polycaprolactone nanofiber bundles in deionized water, freezing and storing the modified polycaprolactone nanofiber bundles at 0 ℃ for 11 hours, taking out the modified polycaprolactone nanofiber bundles, naturally melting the modified polycaprolactone nanofiber bundles at normal temperature, airing the modified polycaprolactone nanofiber bundles in a ventilated and cool place, placing the dried modified polycaprolactone nanofiber bundles in a microwave oven, performing microwave treatment for 15 minutes at the power of 650W, taking out the modified polycaprolactone nanofiber bundles, drying the modified polycaprolactone nanofiber bundles, and weaving to obtain the fiber web.
Preparing modified chitosan: adding 1g of chitosan into every 100ml of 1% acetic acid solution, stirring and dissolving, dropwise adding 1mol/L NaOH solution until the chitosan is swelled and separated out, then adding the chitosan into 50 Vol% isopropanol aqueous solution, stirring and dispersing, heating to 80 ℃, adding epoxypropyltrimethylammonium chloride for 3 times, adding epoxypropyltrimethylammonium chloride with the same mass as the chitosan every time, stirring and reacting for 8 hours, precipitating the reaction solution by using an acetone-ethanol mixed solution, centrifuging, washing and drying to obtain the modified chitosan, wherein the acetone-ethanol mixed solution is obtained by stirring and mixing acetone and ethanol according to the volume ratio of 7: 3.
The preparation of the butyramide-modified hyaluronic acid was the same as in example one.
Preparing a non-woven fabric surface layer: the fiber is loosened, carded and then laid into a fiber web, and the fiber web is hot rolled by point bonding by adopting a conventional technology to obtain a non-woven fabric surface layer.
Preparation of the fiber skeleton layer: the fiber skeleton layer is prepared by overlapping a plurality of fiber webs together, soaking the fiber webs in a fluffy softening agent, performing ultrasonic treatment for 6 hours under an intermittent pulse type ultrasonic wave with the frequency of 25KHz and the power of 100W, taking out the fiber skeleton layer, and performing natural air drying on the fiber skeleton layer, wherein the pulse working time of the intermittent pulse type ultrasonic wave is 3s, and the pulse interval time is 5 s.
Filling: adding 1g of modified chitosan into every 50ml of 0.5 wt% acetic acid solution, stirring and dissolving, then adding glycerol and glutaraldehyde, wherein the mass ratio of the glycerol to the glutaraldehyde is 3:2:0.1 in the embodiment, stirring for 20min by using a foaming device to obtain a modified chitosan solution, adding butyramide-modified hyaluronic acid into deionized water, stirring and dissolving, then adding double-bonded dopamine, dropwise adding the modified chitosan solution, and obtaining a hemostatic gel precursor solution after dropwise adding, wherein the mass ratio of the butyramide-modified hyaluronic acid, the double-bonded dopamine, the modified chitosan and the deionized water is 3:1:5:10, placing the fiber skeleton layer into a mold, pouring the hemostatic gel precursor solution into the mold, standing for 12h under the ultraviolet light condition, and freeze-drying to obtain the fiber skeleton layer filled with the hemostatic gel.
Preparing a hemostatic sponge: and heating the prepared fiber framework layer filled with the hemostatic gel to 35 ℃, covering a non-woven fabric surface layer, heating to 55 ℃, preserving heat for 5min, taking out and cooling to obtain the hemostatic sponge.
EXAMPLE III
Preparing modified polycaprolactone nanofibers: respectively stirring and dissolving polycaprolactone and polylactic acid modified silk fibroin in hexafluoroisopropanol according to a mass ratio of 7:3 to obtain spinning solution with the total mass fraction of 8% of polycaprolactone and polylactic acid modified silk fibroin, transferring the spinning solution into an injector, and performing electrostatic spinning under the conditions that the propelling speed is 0.5ml/h, the spinning electrostatic pressure is 20KV and the acceptance distance is 15cm to obtain the modified polycaprolactone nanofiber.
Preparation of the fiber web: aggregating the modified polycaprolactone nanofibers to form modified polycaprolactone nanofiber bundles with the diameter of 0.1mm, completely soaking the modified polycaprolactone nanofiber bundles in deionized water, freezing and storing for 12 hours at-10 ℃, then taking out, naturally melting at normal temperature, airing the modified polycaprolactone nanofiber bundles in a ventilated and cool place, placing the dried modified polycaprolactone nanofiber bundles in a microwave oven for microwave treatment at the power of 650W for 20 minutes, taking out, drying and weaving to obtain the fiber mesh.
The modified chitosan was prepared as in example one.
The preparation of the butyramide-modified hyaluronic acid was the same as in example one.
Preparing a non-woven fabric surface layer: the fiber is loosened, carded and then laid into a fiber web, and the fiber web is hot rolled by point bonding by adopting a conventional technology to obtain a non-woven fabric surface layer.
Preparation of the fiber skeleton layer: the fiber skeleton layer is prepared by overlapping a plurality of fiber webs together, soaking the fiber webs in a fluffy softening agent, performing ultrasonic treatment for 4 hours under an intermittent pulse type ultrasonic wave with the frequency of 25KHz and the power of 100W, taking out the fiber skeleton layer, and performing natural air drying on the fiber skeleton layer, wherein the pulse working time of the intermittent pulse type ultrasonic wave is 3s, and the pulse interval time is 5 s.
Filling: adding 1g of modified chitosan into every 50ml of 0.5 wt% acetic acid solution, stirring and dissolving, then adding glycerol and glutaraldehyde, wherein the mass ratio of the glycerol to the glutaraldehyde is 3:2:0.1 in the embodiment, stirring for 20min by using a foaming device to obtain a modified chitosan solution, adding butyramide-modified hyaluronic acid into deionized water, stirring and dissolving, then adding double-bonded dopamine, dropwise adding the modified chitosan solution, and obtaining a hemostatic gel precursor solution after dropwise adding, wherein the mass ratio of the butyramide-modified hyaluronic acid, the double-bonded dopamine, the modified chitosan and the deionized water is 3:1:5:10, placing the fiber skeleton layer into a mold, pouring the hemostatic gel precursor solution into the mold, standing for 12h under the ultraviolet light condition, and freeze-drying to obtain the fiber skeleton layer filled with the hemostatic gel.
Preparing a hemostatic sponge: heating the prepared fiber skeleton layer filled with the hemostatic gel to 30 ℃, covering a non-woven fabric surface layer, heating to 50 ℃, preserving heat for 5min, taking out and cooling to obtain the hemostatic sponge.
Although the present invention has been described in detail with reference to the preferred embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the spirit and scope of the invention as defined in the appended claims. The techniques, shapes, and configurations not described in detail in the present invention are all known techniques.
Claims (9)
1. The hemostatic sponge for the anesthesia department is characterized by comprising a non-woven fabric surface layer and a fiber framework layer, wherein the fiber framework layer comprises a plurality of overlapped fiber nets, the fiber nets are formed by weaving modified polycaprolactone nano fibers and have porous network-shaped structures, hemostatic gel is filled in gaps of the fiber framework layer, and the hemostatic gel is obtained by compounding and crosslinking butyramide-modified hyaluronic acid, double-bonded dopamine and modified chitosan and has mutually communicated porous network-shaped structures.
2. The hemostatic sponge for anesthesia department as claimed in claim 1, wherein the mass ratio of the butyrylamide-modified hyaluronic acid, the doubly-bonded dopamine and the modified chitosan is 3:1: 5.
3. The hemostatic sponge for anesthesia department as claimed in claim 2, wherein the modified chitosan is prepared by modifying chitosan with quaternary ammonium salt, and the quaternary ammonium salt is any one of 3-chloro-2-hydroxypropyl trimethyl ammonium chloride and epoxypropyl trimethyl ammonium chloride.
4. The hemostatic sponge for anesthesia department as claimed in claim 3, wherein the modified polycaprolactone nanofiber is prepared by electrospinning polyhexamethylene lactone and modified silk fibroin as main raw materials, and the modified silk fibroin is prepared by modifying silk fibroin by polylactic acid.
5. The hemostatic sponge for anesthesia department as claimed in claim 4, wherein the non-woven fabric surface layer is mainly made of fiber by point bonding and hot rolling, and the fiber is one or more of polylactic acid fiber, polyurethane fiber, polyvinyl alcohol fiber and cellulose acetate fiber.
6. The preparation method of the hemostatic sponge for anesthesia department as claimed in any one of claims 1 to 5, comprising the steps of:
preparing a non-woven fabric surface layer: opening and carding fibers, then paving the fibers into a fiber web, and then carrying out point bonding and hot rolling on the fiber web to obtain a non-woven fabric surface layer;
preparation of the fiber skeleton layer: overlapping multiple layers of fiber nets together, soaking the fiber nets in a fluffy softening agent, performing ultrasonic treatment for 4-6 hours under intermittent pulse type ultrasonic waves, taking out the fiber nets, and naturally drying the fiber nets to obtain a fiber framework layer;
filling: taking modified chitosan, stirring and dissolving the modified chitosan into 0.5 wt% of acetic acid solution, adding glycerol and a cross-linking agent, stirring for 20min by using a foaming device to obtain a modified chitosan solution, adding butyramide-modified hyaluronic acid into deionized water, stirring and dissolving, adding doubly-bonded dopamine, dropwise adding the modified chitosan solution, obtaining a hemostatic gel precursor solution after dropwise adding is completed, placing a fiber skeleton layer into a mold, pouring the hemostatic gel precursor solution into the mold, standing for 12h under the ultraviolet light condition, and freeze-drying to obtain the fiber skeleton layer filled with the hemostatic gel;
preparing a hemostatic sponge: heating the prepared fiber skeleton layer filled with hemostatic gel to 30-35 deg.C, covering with non-woven fabric surface layer, heating to 50-60 deg.C, keeping the temperature for 5min, taking out, and cooling to obtain hemostatic sponge.
7. The method for preparing hemostatic sponge for anesthesia department as claimed in claim 6, wherein the frequency of intermittent pulse type ultrasonic wave is 25KHz, power is 100W, pulse working time is 3s, and pulse interval time is 5 s.
8. The method for preparing a hemostatic sponge for anesthesia department as claimed in claim 7, wherein the method for preparing the fiber web comprises: aggregating the modified poly caprolactone nano fibers to form modified poly caprolactone nano fiber bundles with the diameter of 0.1-0.2mm, soaking the modified poly caprolactone nano fiber bundles in deionized water, freezing and storing for 10-12h at-10-0 ℃, then taking out, naturally melting at normal temperature, airing the modified poly caprolactone nano fiber bundles in a ventilated and cool place, placing the dried modified poly caprolactone nano fiber bundles in a microwave oven for microwave treatment for 15-20min, taking out, drying and weaving to obtain the fiber mesh.
9. The hemostatic sponge for anesthesia department according to claim 8, wherein the preparation method of the modified polycaprolactone nanofiber comprises: respectively stirring and dissolving the polycaprolactone and the polylactic acid modified silk fibroin in hexafluoroisopropanol according to the mass ratio of 7:3 to obtain spinning solution with the mass fraction of 8%, transferring the spinning solution into an injector, and performing electrostatic spinning to obtain the modified polycaprolactone nanofiber.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911023115.1A CN110787317A (en) | 2019-10-25 | 2019-10-25 | Department of anesthesia uses hemostatic sponge |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911023115.1A CN110787317A (en) | 2019-10-25 | 2019-10-25 | Department of anesthesia uses hemostatic sponge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110787317A true CN110787317A (en) | 2020-02-14 |
Family
ID=69441259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911023115.1A Pending CN110787317A (en) | 2019-10-25 | 2019-10-25 | Department of anesthesia uses hemostatic sponge |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110787317A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112168494A (en) * | 2020-09-27 | 2021-01-05 | 西安工程大学 | 3D spacer fabric-aerogel composite medical dressing and preparation method thereof |
| CN112717194A (en) * | 2020-12-30 | 2021-04-30 | 河南亚都实业有限公司 | Degradable chitosan-based composite hemostatic film |
| CN113069589A (en) * | 2021-02-22 | 2021-07-06 | 中国科学院大学温州研究院(温州生物材料与工程研究所) | Biodegradable antibacterial hemostatic sponge |
| CN114681663A (en) * | 2020-12-31 | 2022-07-01 | 广州迈普再生医学科技股份有限公司 | Multifunctional composite wound dressing and preparation method thereof |
| CN115335093A (en) * | 2020-03-02 | 2022-11-11 | 伊诺特纳皮株式会社 | Hemostatic device and method of making same |
| CN116077495A (en) * | 2023-02-10 | 2023-05-09 | 四川大学华西医院 | External anesthetic, preparation method thereof and auxiliary material containing same |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491914A (en) * | 2014-12-25 | 2015-04-08 | 中国人民解放军第四军医大学 | Porous complex gel-nanofiber oxygen permeation dressing and preparation method thereof |
| CN105641733A (en) * | 2015-12-29 | 2016-06-08 | 山东康力医疗器械科技有限公司 | Preparation method for compound antibacterial haemostatic wound dressing |
| CN108187120A (en) * | 2018-02-06 | 2018-06-22 | 重庆医科大学附属永川医院 | A kind of medical analgesic hemostatic dressing of department of anesthesia and preparation method thereof |
| CN109125793A (en) * | 2018-08-21 | 2019-01-04 | 四川力智久创知识产权运营有限公司 | A kind of department of anesthesia's medical stick proof hemostatic sponge and preparation method thereof |
| CN109629037A (en) * | 2018-12-10 | 2019-04-16 | 武汉大学 | Modified polycaprolactone nano fiber scaffold of a kind of triazine fibroin albumen and the preparation method and application thereof |
-
2019
- 2019-10-25 CN CN201911023115.1A patent/CN110787317A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491914A (en) * | 2014-12-25 | 2015-04-08 | 中国人民解放军第四军医大学 | Porous complex gel-nanofiber oxygen permeation dressing and preparation method thereof |
| CN105641733A (en) * | 2015-12-29 | 2016-06-08 | 山东康力医疗器械科技有限公司 | Preparation method for compound antibacterial haemostatic wound dressing |
| CN108187120A (en) * | 2018-02-06 | 2018-06-22 | 重庆医科大学附属永川医院 | A kind of medical analgesic hemostatic dressing of department of anesthesia and preparation method thereof |
| CN109125793A (en) * | 2018-08-21 | 2019-01-04 | 四川力智久创知识产权运营有限公司 | A kind of department of anesthesia's medical stick proof hemostatic sponge and preparation method thereof |
| CN109629037A (en) * | 2018-12-10 | 2019-04-16 | 武汉大学 | Modified polycaprolactone nano fiber scaffold of a kind of triazine fibroin albumen and the preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| DONGLIN GAN等: "Mussel-Inspired Contact-Active Antibacterial Hydrogel with High Cell Affinity, Toughness, and Recoverability", 《ADV. FUNCT. MATER.》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115335093A (en) * | 2020-03-02 | 2022-11-11 | 伊诺特纳皮株式会社 | Hemostatic device and method of making same |
| CN112168494A (en) * | 2020-09-27 | 2021-01-05 | 西安工程大学 | 3D spacer fabric-aerogel composite medical dressing and preparation method thereof |
| CN112717194A (en) * | 2020-12-30 | 2021-04-30 | 河南亚都实业有限公司 | Degradable chitosan-based composite hemostatic film |
| CN114681663A (en) * | 2020-12-31 | 2022-07-01 | 广州迈普再生医学科技股份有限公司 | Multifunctional composite wound dressing and preparation method thereof |
| CN114681663B (en) * | 2020-12-31 | 2023-05-05 | 广州迈普再生医学科技股份有限公司 | Multifunctional composite wound dressing and preparation method thereof |
| CN113069589A (en) * | 2021-02-22 | 2021-07-06 | 中国科学院大学温州研究院(温州生物材料与工程研究所) | Biodegradable antibacterial hemostatic sponge |
| CN116077495A (en) * | 2023-02-10 | 2023-05-09 | 四川大学华西医院 | External anesthetic, preparation method thereof and auxiliary material containing same |
| CN116077495B (en) * | 2023-02-10 | 2024-03-19 | 四川大学华西医院 | External anesthetic, preparation method thereof and auxiliary material containing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110787317A (en) | Department of anesthesia uses hemostatic sponge | |
| CN111529748B (en) | Medical composite dressing for wound repair and preparation method thereof | |
| CN108187120B (en) | Anesthesia department medical pain-relieving and bleeding-stopping dressing and preparation method thereof | |
| CN104491914B (en) | A kind of porous pluralgel-nanofiber oxygen flow dressing and preparation method thereof | |
| CN107469131A (en) | A kind of calcium alginate biology based composite dressing for medical use and preparation method thereof | |
| CN103550817B (en) | A kind of Bacterial cellulose/shitosan composite sponge dressing and preparation method thereof | |
| CN103154347B (en) | Hydrogel fibres and fibrous structures | |
| CN107376000B (en) | Microfibre state hemostatic material and preparation method thereof and hemostatic article | |
| CN110088367B (en) | Antibacterial yarn and antibacterial fabric | |
| CN1830409A (en) | Emergency wound dressing and its preparation method | |
| CN1533751A (en) | Trauma dressing for hematischesis and its preparation method | |
| CN102908653A (en) | Preparation method of antiseptic dressing for deep infection wound | |
| CN106983902A (en) | A kind of novel nano composite wound bandage | |
| CN105031714A (en) | Adhesive bandage and method for manufacturing same | |
| CN109731121A (en) | A kind of preparation method of the cellulose containing mesoporous silicon oxide and chitosan combine dressing | |
| CN113058070B (en) | Rapid hemostatic dressing and preparation method thereof | |
| CN104383585B (en) | A kind of three-dimensional manometer composite adhesive bandage and preparation and application thereof | |
| JP2021518803A (en) | Chitosan fibrous sponge structure medical dressing and its manufacturing method | |
| CN103418024A (en) | Novel absorbent medical material | |
| CN114225088A (en) | Composite multilayer dressing and preparation method and application thereof | |
| CN106975098B (en) | Composite polysaccharide hemostatic composition and preparation method and application thereof | |
| CN105640705A (en) | Composite functional surgical dressing | |
| CN105536030A (en) | Dressing chip with hemostasis and restoration promoting functions and preparation method thereof | |
| CN106215221A (en) | Oligochitosan gelatin akermanite nanofiber biological dressing and preparation method thereof | |
| CN106729930A (en) | A kind of compound hydrophilic fibre dressing and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200214 |